Cell and Gene Therapy Market to Surpass US$ 35.4 Billion by 2026

Cell and gene therapy plays a major role in modern healthcare, as they provide concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.

Read report Overview @ https://www.coherentmarketinsights.com/market-insight/cell-and-gene-therapy-market-2475

Gene therapy aims at influencing the course of various genetic and acquired disorders at the genetic level whereas cell therapy targets various diseases at the cellular level i.e. by restoration of a certain cell population or using cells as carriers of therapeutic carrier. High prevalence of cardiovascular disease is expected to propel demand for cell and gene therapy, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to WHO, in 2012, cancer was the second leading cause of morbidity and mortality globally, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths, worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.

Furthermore, introduction of effective guidelines is expected to propel growth of the global cell and gene therapy market over the forecast period. For instance, the U.S. Food and Drug Administration (FDA) included around 28 guidelines documents from 1998 to 2018 regarding various cell and gene therapies.

Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2475

The global cell and gene therapy market is expected to exhibit a CAGR of 21.9% over the forecast period, owing to increasing prevalence of cardiovascular diseases, cancer, and neurological disorders

Among therapy type, the gene therapy segment held a dominant position in the cell and gene therapy market in 2018. For instance, in November 2018, Pharma Intelligence Company estimated that around 55% of the pipeline is of gene therapy, majorly medicines that are delivered by in vivo.

Among indication, cancer segment held a dominant position in the cell and gene therapy market in 2018, as majority of cell and gene therapies consist of cancer medicines in development stage

Free Sample Report + All Related Graphs & Charts @ https://www.coherentmarketinsights.com/insight/request-sample/2475 

Key players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST

Detailed Segmentation:

Global Cell and Gene Therapy Market, By Therapy Type:
Cell Therapy
Stem Cells
T Cells
Dendritic Cells
NK Cells
Tumor Cells
Gene Therapy
Global Cell and Gene Therapy Market, By Indication:
Cardiovascular Disease
Cancer
Genetic Disorder
Infectious Disease
Neurological Disorders
Others
Global Cell and Gene Therapy Market, By Scale of Operation:
In House
Outsourced

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.